Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. - sprookjes - yvandenbroek - TriplyDB

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

http://www.wikidata.org/entity/Q37205309

about

Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.Update on meningiomas.EGFR soluble isoforms and their transcripts are expressed in meningiomas.EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma The Role of Mifepristone in Meningiomas Management: A Systematic Review of the Literature Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Steroid Receptor Coactivator-3 (SRC-3/AIB1) as a Novel Therapeutic Target in Triple Negative Breast Cancer and Its Inhibition with a Phospho-Bufalin Prodrug.Intratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomas Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005.Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma.Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma Expression of CD163 prevents apoptosis through the production of granulocyte colony-stimulating factor in meningioma.Human epidermal growth factor receptor 2/neu protein expression in meningiomas: An immunohistochemical study.Treatment recommendations for primary extradural meningiomas.Atypical and anaplastic meningiomas treated with bevacizumab.Chemotherapy: What is its role in meningioma?Erlotinib: early clinical development in brain cancer.Medical management of meningiomas.Primary extradural meningioma presenting as a neck mass: Case report and review of the literature.Predictors of Treatment Response and Survival Outcomes in Meningioma Recurrence with Atypical or Anaplastic Histology.Assessment of Brain Tumor Response: RANO and Its Offspring.Activation of multiple growth factor signalling pathways is frequent in meningiomas.Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution.Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake Meningioma.Clinicopathological evaluation of cyclooxygenase-2 expression in meningioma: immunohistochemical analysis of 76 cases of low and high-grade meningioma.Systemic therapy for recurrent meningioma.New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas.An overview of meningiomas An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular signatures Emerging Medical Treatments for Meningioma in the Molecular Era

P2860

Q27853219-9E26ADA7-67BC-42AC-BA84-8FCA68533237 Q30361848-7F5BA76B-6AAD-4031-801F-6C7EE18050D9 Q30393860-DDC46CBE-094D-4702-A0E3-966FC9ED389E Q30438136-EAF11545-AAF9-4B03-9316-AF4FECD57CBA Q30450038-07D8C83D-722F-4FB3-9C30-B18752990572 Q30455709-20A5D20D-1625-4FF8-AD7E-7FB6C1B54B7C Q30461960-00BA2B8F-6B9A-4CDE-9EBB-EAE8F7864409 Q31062214-9676D4B4-5928-4974-99F0-E081E7EEB3DC Q33727426-A326DDD2-D9CB-45AC-BB07-D6E50D12D118 Q34246609-1818E254-FAA9-4AC3-9750-E9B3D200EA33 Q34977393-274C2DC6-AB63-4425-93B4-B9A181B2F4A2 Q35683023-DAF2FA01-6A55-4581-AB0C-CA67927E506C Q35788884-C1945086-B211-4C93-A6D7-CB8603BC2A2E Q35796826-9B4E9C04-21EA-45C5-B615-EF7B293AD47F Q35903183-1E5581D7-8DC6-4A69-B1B0-90489025FD85 Q36346636-FD8842AE-B206-4411-8827-95CDE5EB761D Q36618245-F35A5F22-5301-4D4F-B029-5111A1A41803 Q36740517-FFAF27A0-0F93-48C2-822D-B554359BBE87 Q36943867-C1D57140-0D60-4AD7-B036-21B3DB4C470B Q37221158-13C8649D-DEC3-4038-9C92-81BC577279C8 Q37786296-C7025BF6-6E13-4931-9719-0F8A90416820 Q38006444-E149B046-46FE-4A5A-BCA9-C8F7461A82EF Q38053441-3D51EB81-B7B1-4981-A8F5-575758DBEA34 Q38212394-D691BC64-FCD2-4BDF-AC0C-3BA4C5A113B2 Q38233448-AF9CDF1B-BDEB-460E-A911-554CA7C350D7 Q38253859-32A5931A-03AB-4C11-8859-DEAAD16E04AE Q38711744-08A217D6-2C3F-4CA0-B3CC-9381035F612A Q38855020-DE88B744-6FE1-4B6F-AC2B-2A50D8F04CA0 Q38944293-AF13D2F0-AC27-4EB3-876A-8A0A44408C2F Q39172845-5CB6EF74-E01E-4BAC-95A5-F00BDC91E021 Q42702315-E0E93E11-C6C9-4483-8AB6-5F42C74116B1 Q44118008-B02F3464-6189-456F-974E-71989958C802 Q48249218-0E0471A4-A31C-488C-B406-98CB5B0E359D Q48787594-5C384E09-4C4D-485F-8909-35D1FA3C7EA4 Q52646651-99B10545-07F7-42F2-B3AB-D52FB0E1E3FD Q53246945-A3E359F5-2F20-4128-BD49-77DF4D46764F Q54383059-BF11129A-10D9-48C4-9718-3112F566747D Q57163869-8FF4368E-350B-431F-9DD5-51C5BB0A2A4B Q57306913-89614724-606B-432A-B7B3-C2CB57F79826 Q58798211-259E4A13-1820-41F5-BFF6-E893B082001B

P2860

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

http://www.wikidata.org/entity/Q37205309

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 28 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@en

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@nl

type

label

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@en

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@nl

prefLabel

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@en

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.

@nl

P1433

Q37205309-CBDEA157-3BB9-4A49-B2BC-1F7BCCCAA73F

P1476

Q37205309-AB87F96A-3671-4F9F-BCF3-47F70CA509AE

P2093

Q37205309-06298F43-AAE7-4E87-B52D-2E14CF10553D

Q37205309-105EA854-CAA8-4BB0-B45E-CAF6AD8D6EC4

Q37205309-1828B4A5-94B5-4E2F-9064-7A4E7926A3CA

Q37205309-1D679D5A-C8B4-4FAB-93E8-3B9763C05FC4

Q37205309-26D15625-DDDC-4510-8F78-39A203E502F6

Q37205309-2D4AB55D-D25A-4DCD-B39E-8BAC1BABEDF4

Q37205309-325F1E23-52BB-4448-9865-A64A8C89A061

Q37205309-57F62F9E-1FB0-4FBD-A3AD-ED73C79292AC

Q37205309-7D2C6905-EDFD-4E42-BEB6-07BF92D70A5D

Q37205309-A0BF7655-3C82-4D2A-A0A9-46DBCB0DF4B5

P2860

Q37205309-0C3D96A2-CA6C-44A9-A6F9-5B85388CF354

Q37205309-138F6CCD-E3DF-4657-A5BD-3C1D2F46DB88

Q37205309-1429DD57-1208-43A7-A77E-E7920F2D6C76

Q37205309-1D67C092-5AC7-4C38-B7A9-DBFCB0F7C42A

Q37205309-354A7B4C-4963-4D88-AE74-D02F949E7C12

Q37205309-4A57D406-BC39-4C61-B5F8-1B1F8E105F24

Q37205309-6BA60E60-52AA-4E01-993B-7E5579D7EEA9

Q37205309-7A1B00FA-00E7-4736-B4EF-04B3B273D9F3

Q37205309-7FDEE760-B174-40A6-8F61-08EB50374665

Q37205309-85B23BA4-5072-4745-A160-390A69483EC4

P2888

Q37205309-9C7A5055-0DA4-4FE1-A077-059E03C1ECA0

P304

Q37205309-1267C19D-4232-4D5F-A657-42FF8456B9D0

P31

Q37205309-F14E9F9E-6724-4DF2-A5CF-A50644380DE5

P356

Q37205309-59C5802D-C6BB-40D3-9DBB-998D72A5CFED

P433

Q37205309-9D2BD87A-E4B1-47CE-892C-52D36174233F

P478

Q37205309-A72E146F-55E7-4583-BFB1-9926DEC3AF55

P50

Q37205309-0516B97B-BA4F-4588-A909-80F49EB2F88F

Q37205309-40570B0C-44D4-4BE4-B7EA-C482438DC012

P577

Q37205309-6E7B7CEF-E7BB-44EA-ACDF-C6B2B741CBBD

P5875

Q37205309-7EDED5C6-B126-4E76-B938-E649DB81C5C6

P698

Q37205309-2FFA92ED-FEFC-43D1-AB16-67BE94702238

P921

Q37205309-EA99E050-2E7F-4547-8400-1C71BD018103

P932

Q37205309-98F79A31-0F49-4288-8DC4-DAADD6C44722

P356

S11060-009-9948-7

P1433

Journal of Neuro-Oncology

P1476

Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma

@en

P2093

Andrew B Lassman

http://www.w3.org/2001/XMLSchema#string

Andrew D Norden

http://www.w3.org/2001/XMLSchema#string

Frank Lieberman

http://www.w3.org/2001/XMLSchema#string

H Ian Robins

http://www.w3.org/2001/XMLSchema#string

Howard A Fine

http://www.w3.org/2001/XMLSchema#string

Janet Dancey

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Raizer

http://www.w3.org/2001/XMLSchema#string

Kathleen R Lamborn

http://www.w3.org/2001/XMLSchema#string

Kenneth Aldape

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

Diagnosis and treatment of atypical and anaplastic meningiomas: a review.

Temozolomide for treatment-resistant recurrent meningioma.

Salvage chemotherapy with CPT-11 for recurrent meningioma.

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).

The WHO classification of tumors of the nervous system.

Meningioma pathology, genetics, and biology.

Meningioma: current treatment options and future directions.

Molecular pathogenesis of meningiomas.

P2888

s11060-009-9948-7

P304

211-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-009-9948-7

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Lisa M DeAngelis

P577

2009-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225245848

http://www.w3.org/2001/XMLSchema#string

P698

19562255

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

3786190

http://www.w3.org/2001/XMLSchema#string